undamentalytics Newsletter
Sign in

Oscar Health, Inc. (OSCR) stock

Add to watchlist

Add holding +

NYSE: OSCR NYSE Managed Health Care Next results ~November 5, 2026

B Fundamentals grade

Oscar Health, Inc. is a US-listed company in the managed health care industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$31

Forward price-to-earnings vs peers

Base case. Range ~$26–$43. Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings.

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

Oscar Health, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 7 selling1 purchase and 61 sales by directors and officers, last 12 monthsInsider trades
  • Funds258 adding, 147 cuttingOf 62 active managers that changed their stake, 37 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Oscar Health files

Where Oscar Health stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $15.3bn, up 42.8% on a year earlier, faster than the 31.9% growth a quarter earlier. The diluted share count is up 12.1% on a year earlier, which dilutes existing holders. Our price-to-earnings vs peers value is $41.42 a share, against a share price of $30.77.

Source: 10-Q filed August 7, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Oscar Health, Inc.'s trailing-twelve-month revenue grew 42.8% year on year, with a free-cash-flow margin of 28.6%. Where it stands out: change in growth rate of +10.9pp ranks 1 of 8 managed health care companies we cover. Where it lags: change in share count of 12.1% ranks 8 of 8 managed health care companies we cover.

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 189% in the quarter to 2026-06-30, the 3rd beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 42.8% over the last 12 months, against a median of 18.3% for managed health care companies we cover.
  • Growth speeding up. The growth rate is 10.9 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 5.3 points on a year ago.
  • Strong cash generation. 28.6% of revenue turned into free cash flow.
  • Net cash. Cash exceeds long-term debt by $3.6bn.

Things to watch

  • Results due soon. Results are expected around 5 November; the share price can move sharply on the day.
  • Share dilution. Diluted shares rose 12.1% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 67% and a beta of 1.3 against the S&P 500.

Latest results: FY2026 Q2

Filed August 7, 2026
Earnings per share
$1.10 against an average estimate of $0.38: beat by 189.2%
Revenue
$4.88bn, up 70.4% on a year earlier
Share reaction
-7.3% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 5, 2026; average EPS estimate -$0.17

Oscar Health's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+4.6%
  • 1 week+3.5%
  • 1 month+4.8%
  • This year+115.7%
  • 1 year+83.7%
  • 5 years+91.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$15.3B
Operating margin
4.1%
Net margin
3.6%
EPS (TTM, diluted)
$1.91

Growth

Revenue growth
+42.8%
Change in growth rate
+10.9 pts
Share count change
+12.1%

Earnings

Last results
August 6, 2026
Next results (est.)
November 5, 2026

News & updates

Updated November 1, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Our research
  2. Announcement
  3. Announcement
  4. Announcement
  5. Insider trade
  6. Insider trade
  7. Results
  8. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Oscar Health, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value Oscar Health, Inc. as a health plan, with every model that fits that kind of business. Cost of equity 8.5%: the 10-year Treasury yield (4.9%) plus a beta of 0.79 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$31 ~$26–$43 Primary model, counts double
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Combined value Weighted average of the models that apply: the primary model (forward price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$31 ~$26–$43 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Oscar Health, Inc. with health plans in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

37 /100

Weak moat

How hard Oscar Health's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -6.5% of total assets over 6 years.

  • Durability 10 / 20

    Operating margin has been a median -5.1%; its worst year was -34.8%.

  • Cash conversion 15 / 20

    Free cash flow was positive in 6 of 6 years, at a median 9.0% of revenue.

  • Discipline 9 / 20

    The diluted share count rose 223.7% over five years; stock-based pay has been a median 2.4% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (42 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, before the open. Analysts expect revenue of $4.7bn and EPS of −$0.17 (range −$0.40 to $0.07) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $1.94 +215% $18.7bn +60%
Next $2.22 +14% $20.8bn +11%

Next year's EPS estimate has moved +49.1% in 90 days, across 8 analysts.

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.38 $1.10 +189.2%
Mar 2026 $1.10 $2.07 +88.2%
Dec 2025 −$0.92 −$1.24 −34.6%
Sept 2025 −$0.58 −$0.53 +8.6%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

11 analysts, Oct 2026
Buy327%
Hold764%
Sell19%

Monthly trend

  1. Oct 202637111
  2. Sep 202637111
  3. Aug 202637111
  4. Jul 202637111

Counts of recommendations published by analysts covering Oscar Health, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
6.5%
of tradable shares
Days to cover
3.02
at average volume
Short interest, 1 month
+1%
to September 30, 2026
Held by institutions
74%
of shares
Held by insiders
5.2%
of shares
Employees
2,305
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +72.2%

$18.00 on October 31, 2025 to $31.00

ThenNowEffect
Revenue (last 12 months) $10.7bn $15.3bn +42.8%
P/S multiple 0.4x 0.6x +35.2%
Share count 257m 288m −10.8%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

Last 3 years +441.0%

$5.73 on November 3, 2023 to $31.00

ThenNowEffect
Revenue (last 12 months) $5.0bn $15.3bn +208.5%
P/S multiple 0.2x 0.6x +133.5%
Share count 216m 288m −24.9%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20222023202420252026 to date
Return
OSCR−69%+272%+47%+7%+116%
Industry peers (median)+4%−7%−18%−25%+24%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
OSCR33%67%67%42%55%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
OSCR−79%−50%−43%−42%−39%
S&P 500−25%−10%−8%−19%−9%

Worst fall since March 3, 2021: 94% from March 10, 2021 to December 21, 2022. Getting back needed a 1610% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$10.85 – $34.32
From 52-week high
−9.7%
vs 50-day average
−2.2%
vs 200-day average
+31.0%
Volatility (1 year)
67%
Beta vs S&P 500
1.28

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
9 up, 3 down
typical move ±12.5%
After a week
9 up, 3 down
typical move ±13.6%
After a month
9 up, 3 down
typical move ±12.0%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 −7.3% +0.5% +2.2% +7.1%
May 6, 2026 +16.3% +1.1% +31.7% +36.6%
February 10, 2026 +7.4% −0.3% +8.2% +2.7%
November 6, 2025 +4.1% −1.0% −18.1% −1.8%
August 6, 2025 +9.7% +0.7% +8.0% +40.6%
July 22, 2025 +16.5% +0.9% +1.6% +12.1%
May 7, 2025 +30.5% +1.1% +26.5% +18.0%
February 4, 2025 −6.0% +1.1% −15.8% −6.7%
November 7, 2024 −12.9% +1.2% −0.7% +6.4%
August 7, 2024 +7.2% +1.6% +5.6% −1.4%
May 7, 2024 +9.3% +0.1% +20.3% +2.8%
February 7, 2024 +22.7% +0.9% +24.3% +7.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Oscar Health, Inc. in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Oscar Health, Inc.
$5B $10B $15B $20B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $5.4B Revenue (TTM), FY23 Q4: $5.9B Revenue (TTM), FY24 Q1: $6.5B Revenue (TTM), FY24 Q2: $7.2B Revenue (TTM), FY24 Q3: $8.2B Revenue (TTM), FY24 Q4: $9.2B Revenue (TTM), FY25 Q1: $10.1B Revenue (TTM), FY25 Q2: $10.7B Revenue (TTM), FY25 Q3: $11.3B Revenue (TTM), FY25 Q4: $11.7B Revenue (TTM), FY26 Q1: $13.3B Revenue (TTM), FY26 Q2: $15.3B $15.3B

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $5.4B
FY23 Q4 $5.9B
FY24 Q1 $6.5B
FY24 Q2 $7.2B
FY24 Q3 $8.2B
FY24 Q4 $9.2B
FY25 Q1 $10.1B
FY25 Q2 $10.7B
FY25 Q3 $11.3B
FY25 Q4 $11.7B
FY26 Q1 $13.3B
FY26 Q2 $15.3B
Revenue growth, TTM YoY Oscar Health, Inc.
20% 30% 40% 50% 60% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 56.6% Revenue growth, TTM YoY, FY23 Q4: 47.9% Revenue growth, TTM YoY, FY24 Q1: 46.5% Revenue growth, TTM YoY, FY24 Q2: 45.7% Revenue growth, TTM YoY, FY24 Q3: 51.4% Revenue growth, TTM YoY, FY24 Q4: 56.5% Revenue growth, TTM YoY, FY25 Q1: 54.3% Revenue growth, TTM YoY, FY25 Q2: 48.3% Revenue growth, TTM YoY, FY25 Q3: 37.4% Revenue growth, TTM YoY, FY25 Q4: 27.5% Revenue growth, TTM YoY, FY26 Q1: 31.9% Revenue growth, TTM YoY, FY26 Q2: 42.8% 42.8%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 56.6%
FY23 Q4 47.9%
FY24 Q1 46.5%
FY24 Q2 45.7%
FY24 Q3 51.4%
FY24 Q4 56.5%
FY25 Q1 54.3%
FY25 Q2 48.3%
FY25 Q3 37.4%
FY25 Q4 27.5%
FY26 Q1 31.9%
FY26 Q2 42.8%
Operating margin (TTM) Oscar Health, Inc.
-10% -5% 0% 5% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -5.8% Operating margin (TTM), FY23 Q4: -4.0% Operating margin (TTM), FY24 Q1: -0.4% Operating margin (TTM), FY24 Q2: 0.7% Operating margin (TTM), FY24 Q3: 0.7% Operating margin (TTM), FY24 Q4: 0.6% Operating margin (TTM), FY25 Q1: 1.7% Operating margin (TTM), FY25 Q2: -1.2% Operating margin (TTM), FY25 Q3: -1.9% Operating margin (TTM), FY25 Q4: -3.4% Operating margin (TTM), FY26 Q1: 0.1% Operating margin (TTM), FY26 Q2: 4.1% 4.1%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -5.8%
FY23 Q4 -4.0%
FY24 Q1 -0.4%
FY24 Q2 0.7%
FY24 Q3 0.7%
FY24 Q4 0.6%
FY25 Q1 1.7%
FY25 Q2 -1.2%
FY25 Q3 -1.9%
FY25 Q4 -3.4%
FY26 Q1 0.1%
FY26 Q2 4.1%
FCF margin (TTM) Oscar Health, Inc.
-10% 0% 10% 20% 30% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -8.2% FCF margin (TTM), FY23 Q4: -5.1% FCF margin (TTM), FY24 Q1: -1.2% FCF margin (TTM), FY24 Q2: 3.5% FCF margin (TTM), FY24 Q3: 11.0% FCF margin (TTM), FY24 Q4: 10.4% FCF margin (TTM), FY25 Q1: 11.8% FCF margin (TTM), FY25 Q2: 11.2% FCF margin (TTM), FY25 Q3: 6.5% FCF margin (TTM), FY25 Q4: 9.0% FCF margin (TTM), FY26 Q1: 21.0% FCF margin (TTM), FY26 Q2: 28.6% 28.6%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -8.2%
FY23 Q4 -5.1%
FY24 Q1 -1.2%
FY24 Q2 3.5%
FY24 Q3 11.0%
FY24 Q4 10.4%
FY25 Q1 11.8%
FY25 Q2 11.2%
FY25 Q3 6.5%
FY25 Q4 9.0%
FY26 Q1 21.0%
FY26 Q2 28.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0.5 0.5 1.8 4.0 5.9 9.2 11.7 15.3
EBITDA −0.3 −0.4 −0.5 −0.6 −0.2 0.1 −0.4 0.7
Operating income −0.3 −0.4 −0.5 −0.6 −0.2 0.1 −0.4 0.6
Net income −0.3 −0.4 −0.6 −0.6 −0.3 0.0 −0.4 0.6
Diluted EPS −$9.06 −$14.16 −$3.20 −$2.85 −$1.22 $0.10 −$1.69 $1.91
Growth (year on year)
Revenue — −5.2% +297.3% +115.6% +47.9% +56.5% +27.5% +42.8%
Margins
EBITDA margin −51.7% −84.5% −28.8% −14.5% −3.5% 1.0% −3.1% 4.3%
Operating margin −53.1% −86.9% −29.6% −14.9% −4.0% 0.6% −3.4% 4.1%
Net margin −53.5% −87.9% −31.1% −15.3% −4.6% 0.3% −3.8% 3.6%
Free-cash-flow margin −39.2% 45.1% −11.3% 8.9% −5.1% 10.4% 9.0% 28.6%
Cash flow
Cash from operations −0.2 0.2 −0.2 0.4 −0.3 1.0 1.1 4.4
Capital spending 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Free cash flow −0.2 0.2 −0.2 0.4 −0.3 1.0 1.1 4.4
Stock-based pay 0.0 0.0 0.1 0.1 0.2 0.1 0.1 0.1
Free cash flow after stock pay −0.2 0.2 −0.3 0.2 −0.5 0.8 1.0 4.3
Balance sheet
Cash 0.3 0.8 1.1 1.6 1.9 1.5 2.8 4.1
Total debt 0.0 0.1 0.0 0.3 0.3 0.3 0.4 0.4
Net debt (negative = net cash) −0.3 −0.7 −1.1 −1.3 −1.6 −1.2 −2.3 −3.6
Diluted shares 29m 29m 179m 212m 222m 266m 262m 288m
Returned to shareholders
Buybacks 0.0 0.0 0.0 — — — — —
Total returned 0.0 0.0 0.0 — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Dividends, buybacks and capital spending

Diluted share count
+12.1%
year over year
Sales & admin spending
15.9%
of revenue
Days sales outstanding
9 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in managed health care
Last 12 months unless stated OSCR MOH ALHC CLOV HUM ELV Median
Revenue, last 12 months $15.3bn $44.1bn $4.9bn $2.5bn $145.7bn $201.8bn $94.9bn
Revenue growth, last 12 months 42.8% −0.9% 35.9% 54.0% 18.3% 3.6% 14.0%
Revenue growth, 3-year average 45.6% 9.9% 42.2% 420.1% 13.8% 6.2% 12.3%
Revenue growth, latest quarter 70.4% −3.4% 36.7% 55.6% 26.2% 1.4% 14.1%
Gross margin — 12.6% — 24.9% — 89.0% 24.9%
Operating margin 4.1% 0.4% 0.9% −0.7% 1.9% 2.7% 1.4%
Operating margin, 3-year average 1.2% 2.5% −1.3% −4.0% 2.5% 3.8% 1.8%
Net margin 3.6% −0.1% 0.6% −0.7% 0.9% 2.5% 0.8%
Cash from operations / revenue 28.8% 0.8% 2.2% 3.1% 1.7% 3.8% 2.7%
Free-cash-flow margin 28.6% 0.5% 1.6% 3.0% 1.3% 3.2% 2.5%
Free-cash-flow margin, 3-year average 14.4% −0.2% −0.6% −5.2% −0.4% 1.9% 0.6%
Stock pay / revenue 0.5% 0.2% 1.3% 2.9% 0.2% 0.1% 0.2%
Change in share count 12.1% −6.1% 1.6% 6.8% 0.1% −3.3% −0.2%

Median of all 8 companies we cover in managed health care. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

8 managed health care companies
Measure Company Peer median Rank
Revenue growth Growth 42.8% 18.3% 2 of 8
Change in growth rate Growth +10.9pp -1.3pp 1 of 8
Operating margin Profitability 4.1% 1.9% 2 of 8
Net margin Profitability 3.6% 0.9% 1 of 8
Stock pay as % of revenue Cash generation 0.5% 0.2% 6 of 8
Long-term debt as % of assets Balance sheet 3.8% 22.4% 1 of 7
Change in share count Balance sheet 12.1% 0.1% 8 of 8

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$5.7B
Institutions reporting
400
Shares held vs prior quarter
▲ 14.4%
Positions opened / closed
117 / 49

Top buyers and sellers, Q2 2026: 258 institutions bought and 147 sold ; the biggest buyer was D. E. Shaw & Co., Inc (+7.2M shares) and the biggest seller Bit Capital Gmbh (−2.9M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $587M 20.6M 10.3% ▲ 18.9%
T. Rowe Price Investment Management, Inc. $372M 13.0M 6.5% ▲ 11.9%
D. E. Shaw & Co., Inc. $361M 12.6M 6.3% ▲ 130.5%
Vanguard Portfolio Management LLC $315M 11.0M 5.5% ▲ 4.6%
Vanguard Capital Management LLC $302M 10.6M 5.3% ▼ 1.8%
American Century Companies Inc $258M 9.1M 4.5% ▲ 28.8%
Jane Street Group, LLC $182M 6.4M 3.2% ▲ 119.2%
Thrive Capital Management, LLC $181M 6.3M 3.2% 0.0%
Geode Capital Management, LLC $166M 5.8M 2.9% ▲ 15.6%
State Street Corp $165M 5.8M 2.9% ▲ 10.2%
FMR LLC $143M 5.0M 2.5% ▲ 317.0%
Citadel Advisors LLC $121M 4.2M 2.1% ▲ 22.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Oscar Health, Inc.'s complete shareholder register. Values are as reported by the filers ; 3 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $11.9M 1 trade by 1 insider, last 12 months Insider sales History → $150M 61 trades by 7 insiders · 80% under pre-set plans
Net ▼ $138M net selling
Insider Date Trade Shares Price Value
Wittman Vanessa Ames Director September 18, 2026 Sell pre-set plan 25,000 $32.24 $806,000
Schlosser Mario Director September 3, 2026 Sell pre-set plan 31,422 $31.45 $988,222
Mcananey Adam Chief Legal Officer September 3, 2026 Sell pre-set plan 9,092 $31.45 $285,943
Blackley Richard Scott Chief Financial Officer September 3, 2026 Sell pre-set plan 28,869 $31.45 $907,930
Baltrus Victoria Chief Accounting Officer September 3, 2026 Sell pre-set plan 958 $31.45 $30,129
Liang Janet President, Oscar Insurance September 3, 2026 Sell pre-set plan 10,360 $31.45 $325,822
Schlosser Mario Director August 28, 2026 Sell 150,000 $30.79 $4.6M
Schlosser Mario Director August 27, 2026 Sell 600,000 $30.34 $18.2M
Blackley Richard Scott Chief Financial Officer August 18, 2026 Sell 18,750 $31.74 $595,125
Schlosser Mario Director July 1, 2026 Sell pre-set plan 30,228 $31.65 $956,716
Schlosser Mario Director July 1, 2026 Sell pre-set plan 13,672 $30.80 $421,098
Schlosser Mario Director July 1, 2026 Sell pre-set plan 3,600 $29.50 $106,200

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 6, 2026
  • February 10, 2026
  • November 6, 2025
  • August 6, 2025
  • July 22, 2025

Recent SEC filings

Data status

When each part of this page on Oscar Health, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Oscar Health, Inc. in brief

What does Oscar Health, Inc. do?
Oscar Health, Inc. is a US-listed company in the managed health care industry. Its financial year ends in December.
What is Oscar Health, Inc.'s stock ticker?
Oscar Health, Inc. trades under the ticker OSCR on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Oscar Health, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Oscar Health, Inc. reported revenue of $15.3B, 42.8% higher than a year earlier, according to its SEC filings.
What is Oscar Health, Inc.'s free cash flow?
Oscar Health, Inc.'s free-cash-flow margin is 28.6% of revenue over the trailing twelve months.
Who are Oscar Health, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., T. Rowe Price Investment Management, Inc. and D. E. Shaw & Co., Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Oscar Health, Inc.'s market cap?
On November 2, 2026, Oscar Health, Inc.'s market capitalisation was about $8.9B, with a price-to-earnings ratio of 16.2 and net debt of -$3.6B. Market figures come from third-party market data and may be delayed.
Who are Oscar Health, Inc.'s competitors?
In our Managed Health Care peer group, the companies closest to Oscar Health, Inc. are Molina Healthcare, Inc., Alignment Healthcare, Inc., Clover Health Investments, Corp., Humana and Elevance Health. The side-by-side comparison below sets their revenue, margins and growth against Oscar Health, Inc.'s.
Are insiders buying or selling Oscar Health, Inc. stock?
Over the last 12 months, Oscar Health, Inc.'s directors and officers reported 1 open-market purchases and 61 sales on Form 4. The insider trading page charts every trade.
When is Oscar Health, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Oscar Health, Inc. announces its own schedule.